Maybe NVLS sympathy for cash rich Bios. Next? ADVM $222 Mill Cash/Market Cap $108 Mill. I know of no other Bio that comes close to trading so much under cash in bank with no debt. ADVM also has several early trials getting underway. The drug program they are working on came from the company they acquired last year in a mostly stock deal for much higher prices. So the company ended up coming out of that deal pretty good since the stock price is much lower than the Annapurna shareholders recieved. My reason for owning ADVM here like buying a new Biotech IPO for 75% off the IPO price. Since they are flush with cash like a new IPO and many several new trials that will give a boost to the stock price on speculation about positive results. The company already has a nice partnership with REGN.